menu
    • menu
    [{"orgOrder":0,"company":"Elysium Health","sponsor":"Elysium Health","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Elysium Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elysium Health \/ Elysium Health","highestDevelopmentStatusID":"8","companyTruncated":"Elysium Health \/ Elysium Health"},{"orgOrder":0,"company":"Elysium Health","sponsor":"Elysium Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NORWAY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Neurology","graph2":"Undisclosed","graph3":"Elysium Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elysium Health \/ Elysium Health","highestDevelopmentStatusID":"1","companyTruncated":"Elysium Health \/ Elysium Health"},{"orgOrder":0,"company":"Elysium Health","sponsor":"Elysium Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NORWAY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Neurology","graph2":"Undisclosed","graph3":"Elysium Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elysium Health \/ Elysium Health","highestDevelopmentStatusID":"1","companyTruncated":"Elysium Health \/ Elysium Health"},{"orgOrder":0,"company":"Elysium Health","sponsor":"Elysium Health","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"Elysium Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Elysium Health \/ Elysium Health","highestDevelopmentStatusID":"1","companyTruncated":"Elysium Health \/ Elysium Health"},{"orgOrder":0,"company":"Elysium Health","sponsor":"Mayo Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Undisclosed","graph2":"Phase II","graph3":"Elysium Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elysium Health \/ Elysium Health","highestDevelopmentStatusID":"8","companyTruncated":"Elysium Health \/ Elysium Health"},{"orgOrder":0,"company":"Elysium Health","sponsor":"University of Pennsylvania","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Undisclosed","graph2":"Phase I","graph3":"Elysium Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elysium Health \/ University of Pennsylvania","highestDevelopmentStatusID":"6","companyTruncated":"Elysium Health \/ University of Pennsylvania"},{"orgOrder":0,"company":"Elysium Health","sponsor":"University of Exeter","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Undisclosed","graph2":"Phase I","graph3":"Elysium Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elysium Health \/ University of Exeter","highestDevelopmentStatusID":"6","companyTruncated":"Elysium Health \/ University of Exeter"},{"orgOrder":0,"company":"Elysium Health","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Dietary Supplement","year":"2017","type":"Inapplicable","leadProduct":"Basis","moa":"Undisclosed","graph1":"Nephrology","graph2":"Undisclosed","graph3":"Elysium Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Elysium Health \/ Elysium Health","highestDevelopmentStatusID":"1","companyTruncated":"Elysium Health \/ Elysium Health"},{"orgOrder":0,"company":"Elysium Health","sponsor":"KGK Science","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Dietary Supplement","year":"2016","type":"Inapplicable","leadProduct":"Basis 250","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Elysium Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elysium Health \/ KGK Science","highestDevelopmentStatusID":"6","companyTruncated":"Elysium Health \/ KGK Science"},{"orgOrder":0,"company":"Elysium Health","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Dietary Supplement","year":"2018","type":"Inapplicable","leadProduct":"NRPT","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"Elysium Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elysium Health \/ Nutrasource","highestDevelopmentStatusID":"1","companyTruncated":"Elysium Health \/ Nutrasource"},{"orgOrder":0,"company":"Elysium Health","sponsor":"University of Oxford","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Elysium Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elysium Health \/ University of Oxford","highestDevelopmentStatusID":"1","companyTruncated":"Elysium Health \/ University of Oxford"}]

    Find Clinical Drug Pipeline Developments & Deals by Elysium Health

    Menu

    Elysium Health

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Elysium Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Elysium Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nicotinamide Riboside

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Recipient : University of Copenhagen

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Slow Age: Interventions to Slow Aging in Humans

                            Details : Nicotinamide Riboside is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Aging.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 26, 2022

                            Lead Product(s) : Nicotinamide Riboside

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Recipient : University of Copenhagen

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Elysium Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Elysium Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Sponsor : University of Oxford

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Elysium Health™ Announces Research Partnership with the University of Oxford for the Purpose of Developing E...

                            Details : Developing Elysium Health's proprietary algorithmic platform for epigenetic examination (APEX), and the company's biological age measure Index, Elysium Health plans to utilize the VITACOG biobank to explore the development and commercialization of novel ...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            March 23, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Sponsor : University of Oxford

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Elysium Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Elysium Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nicotinamide Riboside

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Recipient : Haukeland University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Trial of Nicotinamide/Pterostilbene Supplement in ALS: The NO-ALS Extension Study

                            Details : Nicotinamide Riboside is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Amyotrophic Lateral Sclerosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 27, 2021

                            Lead Product(s) : Nicotinamide Riboside

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Recipient : Haukeland University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Elysium Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Elysium Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nicotinamide Riboside

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Undisclosed

                            Recipient : University of South Alabama

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effects of a Seven-day BASISâ„¢ Supplementation on Menopausal Syndromes and Measurements of the Urinary Vi...

                            Details : Nicotinamide Riboside is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Menopause.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 12, 2021

                            Lead Product(s) : Nicotinamide Riboside

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Undisclosed

                            Recipient : University of South Alabama

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Elysium Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Elysium Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nicotinamide Riboside

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Recipient : Haukeland University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The NO-ALS Study: a Trial of Nicotinamide/pterostilbene Supplement in ALS.

                            Details : Nicotinamide Riboside is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Amyotrophic Lateral Sclerosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 24, 2020

                            Lead Product(s) : Nicotinamide Riboside

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Recipient : Haukeland University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Elysium Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Elysium Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nicotinamide Riboside

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase II

                            Recipient : Mayo Clinic

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Protection From Acute Kidney Injury (AKI) With Basisâ„¢ Treatment

                            Details : Nicotinamide Riboside is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 13, 2020

                            Lead Product(s) : Nicotinamide Riboside

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase II

                            Recipient : Mayo Clinic

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Elysium Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Elysium Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nicotinamide Riboside

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : University of Exeter

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Basisâ„¢ and High Intensity Interval Training (HIIT) on Muscle Metabolism and Exercise Performan...

                            Details : Nicotinamide Riboside is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 08, 2019

                            Lead Product(s) : Nicotinamide Riboside

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : University of Exeter

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Elysium Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Elysium Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nicotinamide Riboside

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : University of Pennsylvania

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Basis: Evaluating Sirtuin Supplements To Benefit Elderly Trauma Patients (BES2T BET)

                            Details : Nicotinamide Riboside is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 17, 2018

                            Lead Product(s) : Nicotinamide Riboside

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : University of Pennsylvania

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Elysium Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Elysium Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NRPT

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Undisclosed

                            Sponsor : Nutrasource

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Assess the Relationship Between Daily Dosing of NRPT and Changes in Liver Fat in Healthy Volunteers

                            Details : NRPT is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Fatty Liver.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            May 01, 2018

                            Lead Product(s) : NRPT

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Undisclosed

                            Sponsor : Nutrasource

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Elysium Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Elysium Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Basis

                            Therapeutic Area : Nephrology

                            Study Phase : Undisclosed

                            Recipient : Massachusetts General Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacokinetics, Pharmacodynamics and Safety of Basis in Acute Kidney Injury Study

                            Details : Basis is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Acute Kidney Injury.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            June 05, 2017

                            Lead Product(s) : Basis

                            Therapeutic Area : Nephrology

                            Highest Development Status : Undisclosed

                            Recipient : Massachusetts General Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth